Strand was started by biological engineers working together at MIT. Building on the idea of creating smart therapies that are capable of making sophisticated decisions, they sought to apply the concept of the emerging field of mRNA therapeutics. This area was untapped by traditional synthetic biology, which led them to build their own mRNA “programming language,” creating the world’s first platform for mRNA smart therapies.
Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
Strand’s mRNA programming technology promises to make mRNA therapies safer and more effective by programming the location, timing, and intensity of therapeutic protein expression inside a patient’s body using mRNA-encoded logic circuits. These circuits can implement cell-type specific expression by sensing and classifying the unique miRNA expression signatures of cells, as well as controlling the dosage of protein expression by responding to exogenously administered small molecules.
Location: United States
Employees: 11-50
Total raised: $308M
Founded date: 2017
Investors 6
| Date | Name | Website |
| - | MassChalle... | masschalle... |
| - | Creative D... | creativede... |
| - | Playground... | playground... |
| - | Playground... | playground... |
| - | DHVC | dh.vc |
| - | Endless Fr... | endlessfro... |
Funding Rounds 5
| Date | Series | Amount | Investors |
| 11.08.2025 | Series B | $153M | Kinnevik |
| 03.12.2022 | Series A | $45M | - |
| 31.07.2022 | - | $52M | - |
| 23.06.2021 | Series A | $52M | Playground... |
| 02.07.2019 | Seed | $6M | - |
Mentions in press and media 27
| Date | Title | Description |
| 18.11.2025 | Playground Global Showcases the Future of Compute in Taiwan | New companies, products and partnerships highlight Taiwan's role in accelerating deep tech TAIPEI, Nov. 18, 2025 /PRNewswire/ -- Playground Global, the leading deep tech venture capital firm, today announced new companies, innovations, and ... |
| 11.08.2025 | Strand Therapeutics: $153 Million Series B Funding Raised To Advance Programmable mRNA Therapeutic Pipeline | Strand Therapeutics has secured $153 million in Series B funding, led by Kinnevik and joined by new and existing investors, raising its total to over $250 million. The funds will support the development of its mRNA therapy pipeline, notably... |
| 08.08.2025 | Top Startup and Tech Funding News Roundup – Week Ending August 8, 2025 | It’s Friday, August 8, 2025, and we’re back with the top startup and tech funding stories that shaped the week. From AI titans locking in multi-billion-dollar rounds to stealth-mode deep tech startups breaking cover with game-changing innov... |
| 07.08.2025 | Strand Therapeutics (Life Sciences, '18-19) has secured $153 million in Series B funding, led by Regeneron, Eli Lilly, and Amgen, to push their programmable mRNA cancer medicines into clinical trials ... | - |
| 07.08.2025 | Top Startup and Tech Funding News – August 7, 2025 | It’s Thursday, August 7, 2025, and we’re back with today’s top startup and tech funding news from across the globe. From programmable mRNA and real-time generative AI to on-orbit defense vehicles and fintech fraud resolution, today’s deals ... |
| 07.08.2025 | Strand Therapeutics Raises $153M in Series B Financing | Strand Therapeutics, a Boston, MA-based company which specializes in new mRNA-based therapeutics, raised $153M in Series B funding. The round was led by Kinnevik, with new investors Regeneron Ventures, ICONIQ, Amgen Ventures, Alderline Grou... |
| 07.08.2025 | Strand Therapeutics Scoops Up $153M Series B | BOSTON, MA, Strand Therapeutics, a leader in next-generation mRNA-based therapeutics, today announced $153 million Series B funding. >> Click here for more funding data on Strand Therapeutics >> To export Strand Therapeutics fu... |
| 28.04.2025 | Strand Therapeutics (Life Sciences, '18-19) has revealed encouraging preclinical findings for its innovative mRNA therapy, STX-003, aimed at treating solid tumor cancers. | - |
| 06.04.2025 | Pillar VC's New Fund: A Catalyst for Scientific Innovation | Pillar VC has struck gold with its latest venture, closing a $175 million Fund IV. This move elevates the firm’s total assets under management to over $500 million. It’s a bold step into the future, one that promises to bridge the gap betwe... |
| 04.04.2025 | Pillar VC: $175 Million Fund IV Closed | Pillar VC recently announced its $175 million Fund IV, bringing the firm’s total assets under management to more than $500 million. And Pillar VC is also introducing three new Venture Partners, and four new Founding Pillars, a group of CEOs... |
Show more